FDA Advisory Committee Recommends Approval of Aegerion’s Drug - Lomitapide for Treatment of Homozygous Familial Hypercholesterolemia

The FDA Advisory Committee voted 13-2 in favor of approving lomitapide in patients with homozygous familial hypercholesterolemia (HoFH).

HoFH patients have a genetic deficiency that leads to fatal levels of bad cholesterol.

The Advisory Committee is a panel of experts that reviews data concerning the safety and effectiveness of a drug and makes appropriate recommendations to the FDA.

The overwhelmingly positive vote supports the adequacy of efficacy and safety data of lomitapide and validates the benefit of Aegerion’s drug in severe patients.

FDA is not required to follow the advice of the Advisory Committee, though it often does.
FDA plans to complete its review of lomitapide by December 29, 2012.

AEGR stock is up 50% over last 5 days.

Please consult attachment for the full announcement

Aegerion Pharmaceuticals, Inc.

Aegerion Pharmaceuticals, Inc.
Cardiovascular drug development

Latest News

MVM announces partial sale of its holding in Ambio

MVM Partners announces the partial sale of its holding in Ambio to The Carlyle Group

Alliance Pharma acquires Nizoral rights in APAC region

Alliance Pharma plc (AIM: APH), the specialty pharmaceutical company, is pleased to announce that it has agreed to acquire exclusive marketing rights to Nizoral, a medical, anti-dandruff shampoo brand, in Asia-Pacific from Janssen Pharmaceutica NV.

Alliance Pharma receives positive opinion for Diclectin

Alliance Pharma plc (AIM: APH), the specialty pharmaceutical company, announces that, following discussions with the Medicines and Healthcare products Regulatory Agency and the Commission on Human Medicines, the Marketing Authorisation Application for Diclectin® is now considered approvable.

Wilson Therapeutics AB announces public offer from Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc., has today, through Alexion Pharma Nordics Holding AB, announced a public cash offer to Wilson Therapeutics’ shareholders for a consideration of SEK 232 per Wilson Therapeutics share in cash (the “Offer”), which corresponds to a total offer value of approximately SEK 6,564 million, based on 28,292,272 shares outstanding.

Clinical study supports the use of Cheetah Medical's technologies

Cheetah Medical, a leader in non-invasive hemodynamic monitoring, has announced the publication of a major clinical study designed to evaluate stroke volume guided resuscitation in ICU patients with severe sepsis and septic shock

Vertos Medical Secures $28m in Latest Round of Funding

Vertos Medical Inc., a leader in the minimally invasive treatment of lumbar spinal stenosis has announced that it has completed a $28 million financing round.